Mifepristone, a Glucocorticoid Receptor Antagonist, Produces Clinical and Metabolic Benefits in Patients with Cushing's Syndrome

Fleseriu, Maria; M. K. Biller, Beverly; W. Findling, James; E. Molitch, Mark; Schteingart, D.E.; Gross, Coleman; behalf of the SEISMIC Study Investigators, on; SEISMIC Study Investigators include, The; J. Auchus, Richard; S. Bailey, Timothy; M. K. Biller, Beverly; B Carroll, Ty; Colleran, Kathleen; G. Fein, Henry; W. Findling, James; Fleseriu, Maria; H. Hamrahian, Amir; Katznelson, Laurence; M. Kerr, Janice; Kipnes, Mark; S. Kirschner, Lawrence; A. Koch, Christian; Lerman, Sam; J. Lyons, Timothy; J. McPhaul, Michael; E. Molitch, Mark; E. Schteingart, David; Brooks Vaughan, T.; E. Weiss, Roy

doi:10.1210/jc.2011-3350

Public

Mifepristone, a Glucocorticoid Receptor Antagonist, Produces Clinical and Metabolic Benefits in Patients with Cushing's Syndrome

Published in The Journal of Clinical Endocrinology & Metabolism • Apr 1, 2012

Authors:

Maria Fleseriu

Beverly M. K. Biller

James W. Findling

Abstract

CONTEXT: Cushing's syndrome (CS) is a disorder associated with significant morbidity and mortality due to prolonged exposure to high cortisol concentrations. OBJECTIVE: Our objective was to evaluate the safety and efficacy of mifepristone, a glucocorticoid receptor antagonist, in endogenous CS. DESI...

Subject

Mifepristone

Antiglucocorticoid

Glucocorticoid

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!